Police conducting Summerside traffic stop seize kilo of suspected MDMA, arrest 2 people
Social Sharing
Two people were arrested after police in Summerside found a large quantity of drugs in a vehicle during a traffic stop this week.
Officers made the stop Tuesday at 6:30 p.m. in relation to an investigation into a stolen vehicle, Summerside Police Services said in a news release.
A 32-year-old man and a 34-year-old woman were arrested at the scene. A search of the vehicle uncovered around one kilogram of what police suspect to be MDMA.
Also known as "molly" or "ecstasy," MDMA is a lab-made drug that has effects similar to stimulants like methamphetamine, according to the National Institute on Drug Abuse in the U.S.
The institute said the drug "is typically sold illicitly as colourful tablets with imprinted logos, capsules, powder, or liquid."
Summerside police said they expect to lay charges of drug possession and possession for the purpose of trafficking against the pair.
Follows record drug bust in Stratford
The seizure comes one day after Charlottetown Police Services announced what's suspected to be the largest known drug bust in P.E.I. history.
On Monday, the capital city's police force seized 2.8 kilograms of crystal methamphetamine, 1 kilogram of fentanyl and 763 grams of cocaine from a residence in Stratford.
Three people believed to be from Ontario, one man and two women, are expected to be charged with possession for the purpose of trafficking in that investigation.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
30-05-2025
- Globe and Mail
PharmAla Biotech Warns Against Fake Products Claiming to be Made by PharmAla
TORONTO, May 30, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (' PharmAla ' or the ' Company ') (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), has become aware of unknown parties illegally retailing a nasal spray online, falsely claiming to be a PharmAla Biotech product and unlawfully using PharmAla logos and trademarks. PharmAla is issuing this warning in order to protect consumers and patients. PharmAla's LaNeo MDMA drug products are exclusively available through a qualified practitioner's prescription and Health Canada authorization and administered under the oversight of medical professionals. PharmAla does not, and will not, sell any products directly to consumers; PharmAla does not currently produce a nasal spray. The contents of any nasal spray purporting to be made by PharmAla are unknown and could be harmful to human health. PharmAla strongly urges any and all users who have purchased any unauthorized product to responsibly dispose of it immediately. PharmAla Biotech's mission remains unchanged: to support individuals with legitimate medical needs with the supply of clinical grade LaNeo™ MDMA through legal and regulated channels. We will continue to advance this mission through our work with clinical trials and Health Canada's Special Access Program (SAP). Qualified medical practitioners seeking access for their patients through the SAP can submit applications directly to Health Canada. Practitioners are also encouraged to register through our dedicated portal at: For more details on Health Canada's Special Access Program for psychedelic-assisted psychotherapy, visit: If you have questions about obtaining legitimate PharmAla products, the special access program, or wish to report suspicious products claiming association with our brand, please reach out to us directly for more information and assistance. About PharmAla PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions, and to develop novel drugs in the same class. PharmAla is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. PharmAla's research and development unit has completed proof-of-concept research into several IP families, including ALA-002, its lead drug candidate. PharmAla is a 'regulatory first' organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. For more information, please contact: Nicholas Kadysh Chief Executive Officer PharmAla Biotech Holdings Inc. Email: press@ Phone: 1-855-444-6362 Website: Neither the CSE nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as 'plans', 'strategy', 'expects' or 'does not expect', 'intends', 'continues', 'anticipates' or 'does not anticipate', or 'believes', or variations of such words and phrases or may contain statements that certain actions, events or results 'will be taken', 'will launch' or 'will be launching', 'will include', 'will allow', 'will be made' 'will continue', 'will occur' or 'will be achieved'. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding the use of proceeds from the Offering, the Company continuing to grow its revenue and the Company building on the success of this past year. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements. Although the Company believes that the expectations reflected in these statements are reasonable, such statements are based on expectations, factors, and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond the Company's control, including but not limited to the risk factors discussed under the heading 'Risk Factors' in the Company's management's discussion and analysis, and elsewhere in this press release, as such factors may be further updated from time to time in our periodic filings, available at which factors are incorporated herein by reference. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement and reflect the Company's expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results, or otherwise, or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.
Toronto Star
29-05-2025
- Toronto Star
CBSA says 67 per cent of drugs seized in month-long operation were coming into Canada
OTTAWA - More than 67 per cent of the drugs seized during a month-long cross-country Canada Border Services Agency operation were coming into Canada from the United States, the agency says. Operation Blizzard took place from Feb. 12 to March 13 and targeted illegal drugs and precursor chemicals transported by mail, air cargo or marine container, the CBSA said in a news release Wednesday. The agency said it focused on shipments going to the United States. CBSA said it conducted over 2,600 seizures across the country and just 17.5 per cent of the total seized was destined for the United States. ARTICLE CONTINUES BELOW The operation included 116 seizures of fentanyl, amounting to 1.73 kilograms of the deadly drug. CBSA said 1.44 kilograms of that fentanyl was headed to the United States. The agency said it also seized methamphetamine, cocaine, heroin, opium, MDMA — also called ecstasy or molly — cannabis and cannabis-related products. 'CBSA personnel work day in and day out to prevent criminal organizations from exploiting our borders,' CBSA president Erin O'Gorman said in the news release. 'With Operation Blizzard, we stopped narcotics, synthetic opioids and fentanyl from reaching communities both at home and across the world.' Operation Blizzard was part of Canada's boosted border plan enacted in response to U.S. President Donald Trump's tariffs, which he linked to the flow of fentanyl. Trump hit Canada with economywide tariffs in March, only to partially walk back the duties a few days later for imports compliant with the Canada-U.S.-Mexico Agreement on trade. Ottawa responded to Trump's initial tariff threat with a $1.3-billion border security plan and named Kevin Brosseau as the new 'fentanyl czar.' ARTICLE CONTINUES BELOW ARTICLE CONTINUES BELOW 'Fentanyl and other illegal drugs pose a threat to our communities and to public safety,' Brosseau said in the Wednesday news release. 'The Canada Border Services Agency, with initiatives like Operation Blizzard, is directly contributing to detect, disrupt and dismantle the fentanyl trade.' Data from U.S. Customs and Border Protection show that fentanyl seizures at the Canada-U.S. border represented less than 0.1 per cent of the total seized between 2022 and 2024. This report by The Canadian Press was first published May 28, 2025.
Cision Canada
28-05-2025
- Cision Canada
CBSA seizes 1.73 kg of fentanyl and 59.73 kg of other narcotics during export-focused Operation Blizzard Français
OTTAWA, ON, May 28, 2025 /CNW/ - The Canada Border Services Agency (CBSA) plays an important role in keeping fentanyl, its precursors and other dangerous drugs off our streets. Today, the CBSA shared the results of Operation Blizzard. Launched as part of Canada's Border Plan, Operation Blizzard was a month-long (February 12 th to March 13 th), cross-country surge operation to intercept fentanyl and other illegal drugs in postal, air cargo and marine containers. During the operation, border services officers examined shipments, with a special focus on mail, air freight and sea containers going to the United States. They acted on increased referrals from CBSA's National Targeting Centre based on risk assessments. In total, the CBSA executed over 2,600 seizures of suspected narcotics and precursors across the country. 67.5% of all seizures made were of illegal narcotics coming to Canada from the United States, while 17.5% were of narcotics going to the United States. These included: 116 fentanyl seizures (1.73 kg), intercepted in British Columbia, Québec and Alberta. Of these seizures, 1.44 kg were on route to the United States and 0.26 kg were destined to other countries 17 meth seizures (5.38 kg and 89 pills) 24 cocaine seizures (13 kg) 26 heroin seizures (0.19 kg) 17 opium seizures (38.84 kg and 11 bottles) 48 MDMA seizures (2.32 kg and 82 pills) 249 cannabis and cannabis related product seizures During this same period, the CBSA shared details about other notable seizures of illegal narcotics: 400 litres of 1,4-butanediol in Vancouver, more commonly known as "liquid ecstasy" or the "date rape drug" 148 kg of methamphetamine at Vancouver International Airport 142 kg of cocaine, (estimated value of $3.5M) from rail containers in Montreal 154 kg (estimated value of $4.6M) of ketamine at the Toronto Pearson International Airport 108 kg of cocaine at the Coutts port of entry 419 kg of suspected cocaine at the Blue Water Bridge port of entry 25 kg of codeine and the precursor chemical ephedrine (estimated value of $1.4 M) 8 kg of suspected Khat at the Ambassador Bridge 1.7 kg of suspected MDMA (ecstasy) (estimated value of $59,640) at the Peace Bridge 10 kg of ketamine (estimated value of $706K) at the Vancouver International Airport 2.7 kg of opium (estimated value of $160k) at the Vancouver International Airport just under 25 kg of meth at the Vancouver International Mail Centre The CBSA will continue to disrupt the supply chain for fentanyl and other illicit drugs through interception of contraband as part of Canada's overarching efforts to strengthen border security and combat organized crime. Quotes "I am committed to serving Canadians by keeping our communities safe, combatting hate, and strengthening our security agencies. Operation Blizzard exemplifies the tireless work of border services officers who defend our borders and our communities every day from dangerous drugs and organized crime groups. " - The Honourable Gary Anandasangaree, Minister of Public Safety "Fentanyl and other illegal drugs pose a threat to our communities and to public safety. The Canada Border Services Agency, with initiatives like Operation Blizzard, is directly contributing to detect, disrupt, and dismantle the fentanyl trade." - Kevin Brosseau, Fentanyl Czar "CBSA personnel work day in and day out to prevent criminal organizations from exploiting our borders. With Operation Blizzard, we stopped narcotics, synthetic opioids and fentanyl from reaching communities both at home and across the world. Our commitment to stopping the flow of illegal drugs is unwavering and our officers will continue to protect our communities from these dangerous substances." - Erin O'Gorman, President, Canada Border Services Agency Quick Facts Fentanyl is a very potent opioid. A few grains can be enough to kill you. It is a dangerous drug that is 20 to 40 times more potent than heroin and 100 times more potent than morphine. This makes the risk of accidental overdose very high. Canada is investing $1.3 billion to bolster security at the border and strengthen the immigration system, all while keeping Canadians safe. The CBSA's response to the opioid crisis includes working with domestic and international law enforcement partners to identify and apprehend individuals, groups, and businesses that are suspected to be involved in the cross border movement of illicit drugs and substances. The CBSA also works with Health Canada in monitoring new and emerging threats of non-regulated substances that may be used for the illegal production of controlled substances, which can lead to scheduling of these chemicals under the Controlled Drugs and Substances Act. Contact the Border Watch Line to report suspicious cross-border activities using our secure web form or by calling 1-888-502-9060 toll-free.
